MD Anderson and Blueprint Medicines Announce Strategic Collaboration to Accelerate BLU-222 Development
July 29, 2021
July 29, 2021
HOUSTON, Texas, July 29 (TNSRes) -- The University of Texas's MD Anderson Cancer Center issued the following news release on July 28, 2021:
* * *
Translational research will focus on advancing therapeutic strategies for Blueprint Medicines' potent and selective CDK2 inhibitor across a broad range of tumor types
* * *
The University of Texas MD Anderson Cancer Center and Blueprint Medicines Corporation today announced a three-year stra . . .
* * *
Translational research will focus on advancing therapeutic strategies for Blueprint Medicines' potent and selective CDK2 inhibitor across a broad range of tumor types
* * *
The University of Texas MD Anderson Cancer Center and Blueprint Medicines Corporation today announced a three-year stra . . .